Oncology Corporate Profile
Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed's product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13).
Website: http://www.affimed.com
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| AFM13 | bi-specific tetravalent antibody | Hodgkin's Lymphoma | II | |
| AFM11 | T-cell receptor | Acute Lymphocytic Leukemia (ALL) | I | |
| AFM13 (+ PD 1) | bi-specific tetravalent antibody | Hodgkin's Lymphoma | I | Merck |
| AFM11 | T-cell receptor | Non-Hodgkin's Lymphoma (NHL) | I | |
| AFM13 | bi-specific tetravalent antibody | T-cell lymphoma | I | |
| AFM24 | EGFRwt receptor | Head & Neck cancer | Preclinical | |
| AFM24 | EGFRwt receptor | Non Small Cell Lung Cancer (NSCLC) | Preclinical |
View additional information on product candidates here »
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
